Upgrade to SI Premium - Free Trial

Form 4 MediWound Ltd. For: Aug 26 Filed by: Hess Shmuel

August 28, 2026 4:02 PM
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Hess Shmuel
(Last) (First) (Middle)
C/O MEDIWOUND LTD.
42 HAYARKON STREET
(Street)
YAVNE 8122745
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
COO & Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares (8) 08/26/2026 S 1,865 D $ 13 0 D
Ordinary Shares (9) 08/27/2026 S 1,979 D $ 12.72 0 D
Ordinary Shares (9) 08/27/2026 S 1,979 D $ 13.126 0 D
Ordinary Shares (1) (10) 4,085 D
Ordinary Shares (2) (10) 3,000 D
Ordinary Shares (3) (10) 3,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy ordinary shares) (4) (8) $ 8.1292 08/26/2026 M 5,000 (4) 12/01/2033 Ordinary Shares 5,000 $ 0 27,000 D
Stock Option (right to buy ordinary shares) (4) (9) $ 8.1292 08/27/2026 M 11,000 (4) 12/01/2033 Ordinary Shares 11,000 $ 0 16,000 D
Stock Option (right to buy ordinary shares) (5) (10) $ 12.729 (5) 02/26/2034 Ordinary Shares 32,681 32,681 D
Stock Option (right to buy ordinary shares) (6) (10) $ 18.54 (6) 02/11/2035 Ordinary Shares 24,000 24,000 D
Stock Option (right to buy ordinary shares) (7) (10) $ 17.6 (7) 03/04/2036 Ordinary Shares 31,000 31,000 D
Explanation of Responses:
1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
4. The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
8. The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
9. The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
10. There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only.
/s/ Yaron Meyer, attorney-in-fact 08/28/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EXHIBIT 24.1

Categories

SEC Filings